Logo image of NDRA

ENDRA LIFE SCIENCES INC (NDRA) Stock Fundamental Analysis

NASDAQ:NDRA - Nasdaq - US29273B5003 - Common Stock - Currency: USD

3.16  +0.03 (+0.96%)

Fundamental Rating

2

Overall NDRA gets a fundamental rating of 2 out of 10. We evaluated NDRA against 189 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for NDRA as it has an excellent financial health rating, but there are worries on the profitability. NDRA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

NDRA had negative earnings in the past year.
NDRA had a negative operating cash flow in the past year.
NDRA had negative earnings in each of the past 5 years.
NDRA had a negative operating cash flow in each of the past 5 years.
NDRA Yearly Net Income VS EBIT VS OCF VS FCFNDRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

NDRA has a Return On Assets of -258.47%. This is amonst the worse of the industry: NDRA underperforms 95.77% of its industry peers.
NDRA has a worse Return On Equity (-449.46%) than 86.24% of its industry peers.
Industry RankSector Rank
ROA -258.47%
ROE -449.46%
ROIC N/A
ROA(3y)-126.44%
ROA(5y)-152.36%
ROE(3y)-155.37%
ROE(5y)-200.69%
ROIC(3y)N/A
ROIC(5y)N/A
NDRA Yearly ROA, ROE, ROICNDRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

NDRA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NDRA Yearly Profit, Operating, Gross MarginsNDRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20K -40K -60K -80K

7

2. Health

2.1 Basic Checks

NDRA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NDRA has more shares outstanding
There is no outstanding debt for NDRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NDRA Yearly Shares OutstandingNDRA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
NDRA Yearly Total Debt VS Total AssetsNDRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -39.22, we must say that NDRA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -39.22, NDRA is doing worse than 92.06% of the companies in the same industry.
NDRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -39.22
ROIC/WACCN/A
WACCN/A
NDRA Yearly LT Debt VS Equity VS FCFNDRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

A Current Ratio of 5.67 indicates that NDRA has no problem at all paying its short term obligations.
NDRA has a better Current ratio (5.67) than 80.42% of its industry peers.
A Quick Ratio of 5.67 indicates that NDRA has no problem at all paying its short term obligations.
NDRA's Quick ratio of 5.67 is amongst the best of the industry. NDRA outperforms 85.19% of its industry peers.
Industry RankSector Rank
Current Ratio 5.67
Quick Ratio 5.67
NDRA Yearly Current Assets VS Current LiabilitesNDRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

1

3. Growth

3.1 Past

NDRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.31%, which is quite impressive.
EPS 1Y (TTM)60.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

NDRA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.32% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y46.51%
EPS Next 2Y35.41%
EPS Next 3Y23.32%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NDRA Yearly Revenue VS EstimatesNDRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2021 2022 2026 500K 1M
NDRA Yearly EPS VS EstimatesNDRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -10K -20K -30K -40K

1

4. Valuation

4.1 Price/Earnings Ratio

NDRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NDRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NDRA Price Earnings VS Forward Price EarningsNDRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NDRA Per share dataNDRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80

4.3 Compensation for Growth

NDRA's earnings are expected to grow with 23.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.41%
EPS Next 3Y23.32%

0

5. Dividend

5.1 Amount

NDRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ENDRA LIFE SCIENCES INC

NASDAQ:NDRA (5/23/2025, 12:02:53 PM)

3.16

+0.03 (+0.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-30 2025-04-30
Earnings (Next)08-20 2025-08-20
Inst Owners0.02%
Inst Owner Change912.5%
Ins Owners0.02%
Ins Owner Change0%
Market Cap1.77M
Analysts82.86
Price Target76.5 (2320.89%)
Short Float %21.75%
Short Ratio0.61
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)4.17%
EPS NQ rev (3m)4.17%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.69
P/tB 0.69
EV/EBITDA N/A
EPS(TTM)-90.5
EYN/A
EPS(NY)-15.06
Fwd EYN/A
FCF(TTM)-17.11
FCFYN/A
OCF(TTM)-17.05
OCFYN/A
SpS0
BVpS4.57
TBVpS4.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -258.47%
ROE -449.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-126.44%
ROA(5y)-152.36%
ROE(3y)-155.37%
ROE(5y)-200.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.31%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.67
Quick Ratio 5.67
Altman-Z -39.22
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)84.66%
Cap/Depr(5y)76.8%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.42%
EPS Next Y46.51%
EPS Next 2Y35.41%
EPS Next 3Y23.32%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-2.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y26.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.22%
OCF growth 3YN/A
OCF growth 5YN/A